Overall, after correction for multiple testing, the most consistent suggestive evidence was observed for increased risk of malignant melanoma with genetic liability to renin–angiotensin system agents and decreased risk of cutaneous melanoma with genetic liability to adrenergics, inhalants, and glucocorticoids. The gene discussed is REN; the disease is cutaneous melanoma.